Roche: Patience Still A Part Of Red Sox Plan

December 11, 2014 11:02 PM
Roche: Patience Still A Part Of Red Sox Plan
" BOSTON (CBS) — Let’s start by getting this out of the way: I was not happy that the Red Sox fell short in their bid to sign Jon Lester.

However, it’s time to move on, and that’s what Ben Cherington and his Baseball Ops department have done. Ben quickly made some moves in the pitching market. Lots of folks feel that the Sox still need an ace to replace Lester, and I agree. I do think that patience may be needed. Acquiring an ace is not easy. In fact, it may not happen this offseason. It could happen at the 2015 trade deadline or even next offseason. And, if you look at the Red Sox minor league system, it may not come until one of their young pitchers develops.

A great example of that? Jon Lester.

So, let’s take a look at where the Sox stand as the Winter Meetings end in San Diego, but with still work to be done.


Clay Buchholz Joe Kelly Wade Miley Rick Porcello Justin Masterson

Clearly, it’s no Lester-Lackey 1-2 punch, but it’s vastly improved from what the Sox had to end the season "

Click here to read the whole article

Google related News

Thursday, December 11, 2014 by MedPage Today

Questioning Medicine: Why Is Tamiflu Still Around?

For physicians, this metaphor can be seen in the daily struggle of whether to champion the conversation on how antibiotics are not indicated, or to just go ahead and write for the Z-Pak to get the patient out ... a 4-year stall by Roche, makers of Tamiflu.

Read more
Thursday, December 04, 2014 by Nature

Roche's heart for diabetes

The most potent compounds were also effective against the patient-derived cardiomyocytes. The findings were published in Cell Reports. Iacone told SciBX that the published screen served as proof of concept but that at this point Roche is not following up ...

Read more
Friday, February 01, 2013 by The Economic Times

Cancer drugs made by Emcure, Roche still expensive for patients

MUMBAI: Pune-based Emcure Pharmaceuticals, which had entered into a licensing agreement with Swiss drug maker Roche to sell low-cost versions of its cancer drugs, has not really made the medicines any cheaper, claim health activists, saying they are still ...

Read more
Tuesday, October 21, 2014 by Trefis

Roche’s Cancer Drug Sales Continue To Grow, May Face Competition In Medium Term

It is clear that Roche is still dominant globally when it comes to cancer drugs ... The drug uses a novel technique, under which it leverages patient’s own immune system to fight against the disease. Additionally, Bristol-Myers Squibb recently announced ...

Read more